Navigation Links
Center for Autism and Related Disorders Study Finds Hyperbaric Oxygen Therapy Ineffective Treatment for Children with Autism
Date:11/10/2009

LOS ANGELES, Nov. 10 /PRNewswire/ -- Research conducted by the Center for Autism and Related Disorders, Inc. (CARD), shines new light on the effects of a popular form of hyperbaric oxygen therapy (HBOT) treatment for children with autism and related disorders. The "Randomized Trial of Hyperbaric Oxygen Therapy for Children with Autism" study reveals that HBOT, consisting of 24% oxygen delivered at 1.3 atmospheres of pressure, does not have a significant effect on symptoms of autism. This study was led by Doreen Granpeesheh, PhD, BCBA-D; Jonathan Tarbox, PhD, BCBA-D; Dennis R. Dixon, PhD; Arthur E. Wilke; Michael S. Allen, PsyD; and James Jeffrey Bradstreet, MD, MD (H), FAAFP. It is published in the current issue of Research in Autism Spectrum Disorders.

Autism Spectrum Disorders (ASDs) are characterized by the presence of impaired development in social interaction and communication and the presence of a restricted repertoire of activity and interests. While numerous treatments for ASDs have been proposed, very few have been subjected to rigorous scientific investigation.

HBOT has been recently popularized as a treatment for the symptoms of ASDs. The purpose of this study was to test the hypothesis that HBOT would have a beneficial effect on ASD symptoms in the context of a double-blind placebo-controlled trial.

This randomized double-blind placebo-controlled trial compared HBOT used to deliver 24% oxygen at 1.3 atmospheric pressure (n = 18) to placebo (n = 16) in children with Autistic Disorder. Both direct observational measures of behaviors symptomatic of autism and standardized psychological assessments were used to evaluate the effects of the treatment.

CARD researchers found no differences between HBOT and placebo groups across any of the outcome measures. The present study demonstrates that HBOT delivered at 24% oxygen at 1.3 atmospheric pressure does not result in a clinically significant improvement in the symptoms of Autistic Disorder.

Questions regarding this study should be directed to Dr. Jonathan Tarbox, CARD Director of Research at j.tarbox@centerforautism.com or 818.345.2345.

Media inquires should be directed to Daphne Plump at 661-478-6512 or d.plump@centerforautism.com.

About the Center for Autism and Related Disorders, Inc. (CARD):

CARD is committed to science as the most objective and reliable approach to evaluating treatment for autism. CARD's mission is to conduct empirical research on the assessment and treatment of autism and to disseminate CARD's research findings and derived technology through publication and education of professionals and the public. While the primary focus of CARD's research is ABA-based methods of assessment and treatment, CARD' s overall approach to research includes any topic which may hold promise for producing information that could improve the lives of individuals with autism.

In addition, CARD maintains a reputation as one of the world's largest and most experienced organizations effectively treating children with autism, Asperger's Syndrome, PDD-NOS, and related disorders. Following the principles of Applied Behavior Analysis (ABA), CARD develops individualized treatment plans for children worldwide. For more information about CARD, visit www.centerforautism.com.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE Center for Autism and Related Disorders, Inc.


'/>"/>
SOURCE Center for Autism and Related Disorders, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Health Connect Partners Hosts Hospital O.R. & Surgery Center Conference
2. Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan, Third Consecutive Year
3. United States Olympic Committee Announces D.I.S.C. Sports and Spine Center as an Official Medical Services Provider
4. CDC Awards Vital Prevention Funding to National Sexual Violence Resource Center
5. Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance
6. Clothing Choices Present Barrier to Outdoor Activity for Kids in Child Care Centers
7. Narconon Centers Educate Thousands During Red Ribbon Week
8. Drug Rehab CT - Mountainside Announces the Appointment of Family Wellness Program Director for its Connecticut Addiction Treatment Center
9. LogicalSolutions.net Opens New Enterprise Class Datacenter in Rochester, NY
10. IBM Launches Health Analytics Center
11. World Trade Center Workers Twice as Likely to Have Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Melbourne’s reign as the world’s most liveable ... Unit’s (EIU) annual Liveability Index. , The Index surveys 140 of the world’s cities ... 2006, Melbourne has consistently come in the top three of the index. So what ...
(Date:8/16/2017)... ... August 16, 2017 , ... Connexion Point, a technology-enabled healthcare services company ... fourth consecutive year. With 197% revenue growth over the past three years, ... growing companies. , Previous honors include ranking 86th on the Inc. 500 ...
(Date:8/16/2017)... Rochester, Michigan (PRWEB) , ... August 16, 2017 ... ... treatment options to patients suffering from chronic pelvic pain. In addition to ... various pelvic pain disorders including endometriosis, menorrhagia (abnormal heavy bleeding during menstruation), uterine ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... an annual all-encompassing awards program which recognizes organizations that demonstrate the core values ... of comprehensive award categories. , “As a global company, we are expanding our ...
(Date:8/16/2017)... ... ... “Mom, God's Got This: Jamie's Story” is the creation of published author, Karen F. Norton, ... insatiable appetite for God’s Word. , “I froze between the half walls, shelves on my ... oatmeal. I have one to this day on proud display in my dining room hutch; ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
(Date:7/28/2017)... 2017 EnvoyHealth, a Diplomat company, has partnered with ... CleverCap LITE, a technology designed to improve patient medication ... health technology solutions and services that help track and ... CleverCap LITE offers medication monitoring and control for ... Records date and time ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: